Yongxin optics: Jiamao information plans to reduce its holdings of no more than 500000 shares
Financial Associated Press, Dec. 3 - Yongxin optical announced that as of the disclosure date of the announcement, Jiamao Information Technology Co., Ltd. ("Jiamao information") held 1479423 shares of the company, accounting for 1.339% of the total share capital of the company. Jiamao information plans to reduce its holdings of the company's shares by means of centralized bidding, block trading and other laws and regulations. Within six months after three trading days from the date of disclosure of the reduction plan, the total reduction shall not exceed 500000 shares of the company, accounting for 0.453% of the total share capital of the company.
This text is a result of machine translation.
Related companies：
In-depth
Healthcare
China's First Oral COVID-19 Antiviral Medicine in Dispute
An obscure Chinese company called Genuine Biotech(Chinese: 真实生物) was suddenly put under the spotlight on July 25 when the Chinese authority announced the conditional approval of the company's application for adding the treatment of COVID-19 as a new indication of Azvudine under the special review and approval procedures for drug registration.
Aug 08, 2022 09:00 AM
Jan 30, 2024 07:59 PM
Dec 11, 2023 08:49 PM
Jan 06, 2023 08:30 AM
Jan 05, 2023 07:33 PM
Healthcare, Financials
Fosun Pharma Net Profit down 45% in Q1 2022 as Value of Financial Assets Slumps
Founded in 1994, Shanghai Fosun Pharma is a global pharmaceutical and health group rooted in China and driven by innovation. Its businesses include pharmaceuticals, medical devices and diagnosis, medical and health services. The group covers the pharmaceutical field through participation in Sinopharm Holdings.
Apr 27, 2022 10:55 PM
Briefing Feb 17, 2022 10:08 AM
Yingsi intelligence and Fosun Pharmaceutical reached the first milestone of strategic cooperation: nomination and targeting cd47-sirp α Small molecule compounds of signal pathway
Briefing Jan 24, 2022 02:39 PM
The main force continued to increase its position in lithium battery stocks in the late trading, and sold off banks and pharmaceutical stocks
See more
Read next
Insight
In-depth